MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma

Eleni M. Rettig, Marietta Tan, Shizhang Ling, Raluca Yonescu, Justin A. Bishop, Carole Fakhry, Patrick K. Ha

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Objectives Salivary gland adenoid cystic carcinoma (ACC) is rare, aggressive, and challenging to treat. Many ACCs have a t(6;9) chromosomal translocation resulting in a MYB-NFIB fusion gene, but the clinical significance is unclear. The purposes of this study were to describe the clinicopathologic factors impacting survival and to determine the prevalence and clinical significance of MYB-NFIB fusion. Study Design Case series. Methods Medical records of patients treated for ACC of the head and neck from 1974 to 2011 were reviewed and clinicopathologic data recorded. Fluorescence in situ hybridization (FISH) was used to detect MYB rearrangement in archival tumor tissue as a marker of MYB-NFIB fusion. Results One hundred fifty-eight patients were included, with median follow-up 75.1 months. Median overall survival was 171.5 months (95% confidence interval [CI]=131.9-191.6), and median disease-free survival was 112.0 months (95% CI=88.7-180.4). Advanced stage was associated with decreased overall survival (adjusted ptrend<0.001), and positive margins were associated with decreased disease-free survival (adjusted hazard ratio [aHR]=8.80, 95% CI=1.25-62.12, P = 0.029). Ninety-one tumors were evaluable using FISH, and 59 (65%) had evidence of a MYB-NFIB fusion. MYB-NFIB positive tumors were more likely than MYB-NFIB negative tumors to originate in minor salivary glands (adjusted prevalence ratios=1.51, 95% CI=1.07-2.12, P = 0.019). MYB-NFIB tumor status was not significantly associated with disease-free or overall survival (hazard ratio [HR]=1.53, 95% CI=0.77-3.02, P = 0.22 and HR=0.91, 95% CI=0.46-1.83, P = 0.80, respectively, for MYB-NFIB positive compared with MYB-NFIB negative tumors). Conclusion Stage and margin status were important prognostic factors for ACC. Tumors with evidence of MYB-NFIB fusion were more likely to originate in minor salivary glands, but MYB-NFIB tumor status was not significantly associated with prognosis. Level of Evidence 4. Laryngoscope, 125:E292-E299, 2015

Original languageEnglish (US)
Pages (from-to)E292-E299
JournalLaryngoscope
Volume125
Issue number9
DOIs
StatePublished - Jan 1 2015

Fingerprint

Adenoid Cystic Carcinoma
Neck
Head
Confidence Intervals
Neoplasms
Minor Salivary Glands
Survival
Fluorescence In Situ Hybridization
Disease-Free Survival
Laryngoscopes
Genetic Translocation
Gene Fusion
Salivary Glands
Medical Records

Keywords

  • Adenoid cystic carcinoma
  • disease-free survival
  • minor salivary glands
  • MYB
  • MYB-NFIB fusion gene
  • salivary gland neoplasms
  • survival

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma. / Rettig, Eleni M.; Tan, Marietta; Ling, Shizhang; Yonescu, Raluca; Bishop, Justin A.; Fakhry, Carole; Ha, Patrick K.

In: Laryngoscope, Vol. 125, No. 9, 01.01.2015, p. E292-E299.

Research output: Contribution to journalArticle

Rettig, EM, Tan, M, Ling, S, Yonescu, R, Bishop, JA, Fakhry, C & Ha, PK 2015, 'MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma', Laryngoscope, vol. 125, no. 9, pp. E292-E299. https://doi.org/10.1002/lary.25356
Rettig, Eleni M. ; Tan, Marietta ; Ling, Shizhang ; Yonescu, Raluca ; Bishop, Justin A. ; Fakhry, Carole ; Ha, Patrick K. / MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma. In: Laryngoscope. 2015 ; Vol. 125, No. 9. pp. E292-E299.
@article{2d1e130c887d48ccbb9f19f1f0e36535,
title = "MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma",
abstract = "Objectives Salivary gland adenoid cystic carcinoma (ACC) is rare, aggressive, and challenging to treat. Many ACCs have a t(6;9) chromosomal translocation resulting in a MYB-NFIB fusion gene, but the clinical significance is unclear. The purposes of this study were to describe the clinicopathologic factors impacting survival and to determine the prevalence and clinical significance of MYB-NFIB fusion. Study Design Case series. Methods Medical records of patients treated for ACC of the head and neck from 1974 to 2011 were reviewed and clinicopathologic data recorded. Fluorescence in situ hybridization (FISH) was used to detect MYB rearrangement in archival tumor tissue as a marker of MYB-NFIB fusion. Results One hundred fifty-eight patients were included, with median follow-up 75.1 months. Median overall survival was 171.5 months (95{\%} confidence interval [CI]=131.9-191.6), and median disease-free survival was 112.0 months (95{\%} CI=88.7-180.4). Advanced stage was associated with decreased overall survival (adjusted ptrend<0.001), and positive margins were associated with decreased disease-free survival (adjusted hazard ratio [aHR]=8.80, 95{\%} CI=1.25-62.12, P = 0.029). Ninety-one tumors were evaluable using FISH, and 59 (65{\%}) had evidence of a MYB-NFIB fusion. MYB-NFIB positive tumors were more likely than MYB-NFIB negative tumors to originate in minor salivary glands (adjusted prevalence ratios=1.51, 95{\%} CI=1.07-2.12, P = 0.019). MYB-NFIB tumor status was not significantly associated with disease-free or overall survival (hazard ratio [HR]=1.53, 95{\%} CI=0.77-3.02, P = 0.22 and HR=0.91, 95{\%} CI=0.46-1.83, P = 0.80, respectively, for MYB-NFIB positive compared with MYB-NFIB negative tumors). Conclusion Stage and margin status were important prognostic factors for ACC. Tumors with evidence of MYB-NFIB fusion were more likely to originate in minor salivary glands, but MYB-NFIB tumor status was not significantly associated with prognosis. Level of Evidence 4. Laryngoscope, 125:E292-E299, 2015",
keywords = "Adenoid cystic carcinoma, disease-free survival, minor salivary glands, MYB, MYB-NFIB fusion gene, salivary gland neoplasms, survival",
author = "Rettig, {Eleni M.} and Marietta Tan and Shizhang Ling and Raluca Yonescu and Bishop, {Justin A.} and Carole Fakhry and Ha, {Patrick K.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/lary.25356",
language = "English (US)",
volume = "125",
pages = "E292--E299",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma

AU - Rettig, Eleni M.

AU - Tan, Marietta

AU - Ling, Shizhang

AU - Yonescu, Raluca

AU - Bishop, Justin A.

AU - Fakhry, Carole

AU - Ha, Patrick K.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objectives Salivary gland adenoid cystic carcinoma (ACC) is rare, aggressive, and challenging to treat. Many ACCs have a t(6;9) chromosomal translocation resulting in a MYB-NFIB fusion gene, but the clinical significance is unclear. The purposes of this study were to describe the clinicopathologic factors impacting survival and to determine the prevalence and clinical significance of MYB-NFIB fusion. Study Design Case series. Methods Medical records of patients treated for ACC of the head and neck from 1974 to 2011 were reviewed and clinicopathologic data recorded. Fluorescence in situ hybridization (FISH) was used to detect MYB rearrangement in archival tumor tissue as a marker of MYB-NFIB fusion. Results One hundred fifty-eight patients were included, with median follow-up 75.1 months. Median overall survival was 171.5 months (95% confidence interval [CI]=131.9-191.6), and median disease-free survival was 112.0 months (95% CI=88.7-180.4). Advanced stage was associated with decreased overall survival (adjusted ptrend<0.001), and positive margins were associated with decreased disease-free survival (adjusted hazard ratio [aHR]=8.80, 95% CI=1.25-62.12, P = 0.029). Ninety-one tumors were evaluable using FISH, and 59 (65%) had evidence of a MYB-NFIB fusion. MYB-NFIB positive tumors were more likely than MYB-NFIB negative tumors to originate in minor salivary glands (adjusted prevalence ratios=1.51, 95% CI=1.07-2.12, P = 0.019). MYB-NFIB tumor status was not significantly associated with disease-free or overall survival (hazard ratio [HR]=1.53, 95% CI=0.77-3.02, P = 0.22 and HR=0.91, 95% CI=0.46-1.83, P = 0.80, respectively, for MYB-NFIB positive compared with MYB-NFIB negative tumors). Conclusion Stage and margin status were important prognostic factors for ACC. Tumors with evidence of MYB-NFIB fusion were more likely to originate in minor salivary glands, but MYB-NFIB tumor status was not significantly associated with prognosis. Level of Evidence 4. Laryngoscope, 125:E292-E299, 2015

AB - Objectives Salivary gland adenoid cystic carcinoma (ACC) is rare, aggressive, and challenging to treat. Many ACCs have a t(6;9) chromosomal translocation resulting in a MYB-NFIB fusion gene, but the clinical significance is unclear. The purposes of this study were to describe the clinicopathologic factors impacting survival and to determine the prevalence and clinical significance of MYB-NFIB fusion. Study Design Case series. Methods Medical records of patients treated for ACC of the head and neck from 1974 to 2011 were reviewed and clinicopathologic data recorded. Fluorescence in situ hybridization (FISH) was used to detect MYB rearrangement in archival tumor tissue as a marker of MYB-NFIB fusion. Results One hundred fifty-eight patients were included, with median follow-up 75.1 months. Median overall survival was 171.5 months (95% confidence interval [CI]=131.9-191.6), and median disease-free survival was 112.0 months (95% CI=88.7-180.4). Advanced stage was associated with decreased overall survival (adjusted ptrend<0.001), and positive margins were associated with decreased disease-free survival (adjusted hazard ratio [aHR]=8.80, 95% CI=1.25-62.12, P = 0.029). Ninety-one tumors were evaluable using FISH, and 59 (65%) had evidence of a MYB-NFIB fusion. MYB-NFIB positive tumors were more likely than MYB-NFIB negative tumors to originate in minor salivary glands (adjusted prevalence ratios=1.51, 95% CI=1.07-2.12, P = 0.019). MYB-NFIB tumor status was not significantly associated with disease-free or overall survival (hazard ratio [HR]=1.53, 95% CI=0.77-3.02, P = 0.22 and HR=0.91, 95% CI=0.46-1.83, P = 0.80, respectively, for MYB-NFIB positive compared with MYB-NFIB negative tumors). Conclusion Stage and margin status were important prognostic factors for ACC. Tumors with evidence of MYB-NFIB fusion were more likely to originate in minor salivary glands, but MYB-NFIB tumor status was not significantly associated with prognosis. Level of Evidence 4. Laryngoscope, 125:E292-E299, 2015

KW - Adenoid cystic carcinoma

KW - disease-free survival

KW - minor salivary glands

KW - MYB

KW - MYB-NFIB fusion gene

KW - salivary gland neoplasms

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84939778289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939778289&partnerID=8YFLogxK

U2 - 10.1002/lary.25356

DO - 10.1002/lary.25356

M3 - Article

C2 - 25963073

AN - SCOPUS:84939778289

VL - 125

SP - E292-E299

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 9

ER -